AsthmaSUJOK-ASTHMANCT07746570
SU JOK THERAPY TO IMPROVE DYSPNEA AND INSOMNIA IN ASTHMA
A study testing su jok therapy in people with Asthma and Dyspnea, run by Erzincan Binali Yildirim Universitesi at 1 site in Turkey (Türkiye).
Trial summary
Asthma is a long-term lung disease that can make breathing difficult and can also affect sleep. Even with regular medical treatment, many people with asthma continue to experience shortness of breath and insomnia. Read more about this study
- Who is it for?
- Ages 18 years and older
- What is being tested?
- su jok therapy
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 2 Jan 2026to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18 years or older.
- Diagnosed with asthma by a physician.
- A baseline Visual Analog Scale (VAS) score of 3 or higher for both dyspnea and insomnia.
- Receiving routine asthma treatment.
- Able to communicate in Turkish.
- Able to understand the study procedures and provide written informed consent.
- Willing to participate in the study.
Who cannot join
- Presence of severe cognitive or psychiatric disorders that could interfere with participation.
- Presence of skin lesions, infection, or injury on the hands that would prevent Su Jok therapy.
- Participation in another clinical trial during the study period.
- Withdrawal of consent at any stage of the study.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Erzincan Binali Yıldırım University
Erzincan, Merkez, 24100
About this study
Official title: THE EFFECT OF SU JOK THERAPY ON DYSPNEA AND INSOMNIA IN PATIENTS WITH ASTHMA: A RANDOMIZED CONTROLLED TRIAL
Asthma is a long-term lung disease that can make breathing difficult and can also affect sleep. Even with regular medical treatment, many people with asthma continue to experience shortness of breath and insomnia. This study will examine whether Su Jok therapy, a complementary therapy that applies gentle stimulation to specific points on the hands and feet, can help reduce shortness of breath and improve sleep in people with asthma. Adults with asthma who agree to participate will be randomly assigned to one of two groups. One group will receive Su Jok therapy in addition to their usual care, while the other group will receive usual care only. Researchers will compare changes in breathing difficulty and sleep quality between the two groups.
The results of this study may help determine whether Su Jok therapy can be used as a safe and supportive treatment alongside standard asthma care.
Read the detailed description
Asthma is a chronic inflammatory disease of the airways that is characterized by recurrent episodes of dyspnea, wheezing, cough, and chest tightness. Despite advances in pharmacological treatment, many people with asthma continue to experience persistent symptoms, particularly dyspnea and sleep disturbances, which may negatively affect daily functioning and quality of life.
Complementary therapies are increasingly being investigated as supportive approaches to symptom management. Su Jok therapy is a complementary therapy based on the stimulation of specific points on the hands and feet that correspond to different parts of the body. It has been suggested that this approach may help relieve symptoms and improve overall well-being.
This randomized controlled trial aims to evaluate the effect of Su Jok therapy on dyspnea and insomnia in adults with asthma. Participants will be randomly assigned to either an intervention group receiving Su Jok therapy in addition to routine care or a control group receiving routine care alone. Dyspnea and insomnia will be assessed before and after the intervention using validated measurement instruments. The findings of this study are expected to provide evidence regarding the potential role of Su Jok therapy as a complementary, non-pharmacological intervention for symptom management in individuals with asthma.
- Being tested
- su jok therapy
- Keywords
- Insomnia, INSOMNİA, su jok, asthma
- Medical subject headings
- Asthma, Dyspnea, Sleep Initiation and Maintenance Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
su jok therapyOther
Su Jok therapy was administered by the researcher once daily for five consecutive days in addition to routine asthma care. The intervention involved stimulation of predefined Su Jok correspondence points on the hands according to the study protocol. Each session was performed using standardized procedures to ensure consistency throughout the study.
| Study group | Role | What they receive |
|---|---|---|
| Su Jok Therapy Group | Experimental | Participants in this group will receive routine asthma care plus five consecutive daily sessions of Su Jok therapy. Dyspnea and insomnia symptoms will be assessed daily using the Visual Analog Scale (VAS). Questionnaire data will be collected before the intervention (baseline) and after completion of the intervention (post-test). Receives: Other: su jok therapy |
| Control Group | No intervention | Participants in this group will receive routine asthma care only. Dyspnea and insomnia symptoms will be assessed daily for five consecutive days using the Visual Analog Scale (VAS). Questionnaire data will be collected at baseline and after the study period (post-test). |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dyspnea severity
Dyspnea severity will be assessed using the Visual Analog Scale (VAS). Higher scores indicate greater dyspnea severity.
Measured: Baseline and daily for 5 consecutive days, with post-intervention assessment on Day 5.
Secondary outcomes (1)
Insomnia severity
Insomnia severity will be assessed using the Visual Analog Scale (VAS) and the Insomnia Severity Index (ISI). Higher scores indicate greater insomnia severity.
Measured: Baseline and post-intervention (Day 5).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study start2 Jan 2026
- Primary completion31 Jul 2026
- Study completion1 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AsthmaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Erzincan Binali Yildirim Universitesi
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Demet GÜNEŞ, Erzincan Binali Yildirim Universitesi
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07746570
- Sponsor's protocol ID
- 2025-663
- Acronym
- SUJOK-ASTHMA
- Status last verified
- Aug 2026
- First submitted
- 31 Jul 2026
- Last updated
- 6 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because participant confidentiality and privacy will be protected in accordance with the informed consent and ethics committee approval.
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- THE EFFECT OF SU JOK THERAPY ON DYSPNEA AND INSOMNIA IN PATIENTS WITH ASTHMA: A RANDOMIZED CONTROLLED TRIAL
- ClinicalTrials.gov ID
- NCT07746570
- Acronym / sponsor ID
- SUJOK-ASTHMA / 2025-663
- Keywords
- Insomnia, INSOMNİA, su jok, asthma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Erzincan Binali Yildirim UniversitesiUniversity, hospital or other
- Study start
- 2 Jan 2026 (actual)
- Primary completion
- 31 Jul 2026 (actual)
- Study completion
- 1 Aug 2026 (actual)
- First posted
- 5 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Asthma is a long-term lung disease that can make breathing difficult and can also affect sleep. Even with regular medical treatment, many people with asthma continue to experience shortness of breath and insomnia. This study will examine whether Su Jok therapy, a complementary therapy that applies gentle stimulation to specific points on the hands and feet, can help reduce shortness of breath and improve sleep in people with asthma. Adults with asthma who agree to participate will be randomly assigned to one of two groups. One group will receive Su Jok therapy in addition to their usual care, while the other group will receive usual care only. Researchers will compare changes in breathing difficulty and sleep quality between the two groups.
The results of this study may help determine whether Su Jok therapy can be used as a safe and supportive treatment alongside standard asthma care.
Detailed description
Asthma is a chronic inflammatory disease of the airways that is characterized by recurrent episodes of dyspnea, wheezing, cough, and chest tightness. Despite advances in pharmacological treatment, many people with asthma continue to experience persistent symptoms, particularly dyspnea and sleep disturbances, which may negatively affect daily functioning and quality of life.
Complementary therapies are increasingly being investigated as supportive approaches to symptom management. Su Jok therapy is a complementary therapy based on the stimulation of specific points on the hands and feet that correspond to different parts of the body. It has been suggested that this approach may help relieve symptoms and improve overall well-being.
This randomized controlled trial aims to evaluate the effect of Su Jok therapy on dyspnea and insomnia in adults with asthma. Participants will be randomly assigned to either an intervention group receiving Su Jok therapy in addition to routine care or a control group receiving routine care alone. Dyspnea and insomnia will be assessed before and after the intervention using validated measurement instruments. The findings of this study are expected to provide evidence regarding the potential role of Su Jok therapy as a complementary, non-pharmacological intervention for symptom management in individuals with asthma.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Su Jok Therapy Group | Experimental | Other: su jok therapyParticipants in this group will receive routine asthma care plus five consecutive daily sessions of Su Jok therapy. Dyspnea and insomnia symptoms will be assessed daily using the Visual Analog Scale (VAS). Questionnaire data will be collected before the intervention (baseline) and after completion of the intervention (post-test). |
| Control Group | No intervention | –Participants in this group will receive routine asthma care only. Dyspnea and insomnia symptoms will be assessed daily for five consecutive days using the Visual Analog Scale (VAS). Questionnaire data will be collected at baseline and after the study period (post-test). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults aged 18 years or older.
- Diagnosed with asthma by a physician.
- A baseline Visual Analog Scale (VAS) score of 3 or higher for both dyspnea and insomnia.
- Receiving routine asthma treatment.
- Able to communicate in Turkish.
Key exclusion criteria (4 listed)
- Presence of severe cognitive or psychiatric disorders that could interfere with participation.
- Presence of skin lesions, infection, or injury on the hands that would prevent Su Jok therapy.
- Participation in another clinical trial during the study period.
- Withdrawal of consent at any stage of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| su jok therapySu Jok therapy was administered by the researcher once daily for five consecutive days in addition to routine asthma care. The intervention involved stimulation of predefined Su Jok correspondence points on the hands according to the study protocol. Each session was performed using standardized procedures to ensure consistency throughout the study. | Other | Su Jok Therapy Group |
Primary outcome
Dyspnea severity
Time frame: Baseline and daily for 5 consecutive days, with post-intervention assessment on Day 5.
Dyspnea severity will be assessed using the Visual Analog Scale (VAS). Higher scores indicate greater dyspnea severity.
1 secondary outcome
Insomnia severity
Time frame: Baseline and post-intervention (Day 5).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2026.
- The Effects of Su Jok Therapy on Pain, Fatigue, Insomnia, Nausea, and Vomiting Experienced by Patients With Gastrointestinal System Cancer: A Randomized TrialLink provided by the sponsor.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because participant confidentiality and privacy will be protected in accordance with the informed consent and ethics committee approval.
Related trials for Asthma
RecruitingPhase 1
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Asthma
RecruitingPhase 1
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
Asthma, Mild Asthma
RecruitingPhase 3
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
Asthma Control
Active, not recruitingPhase 2/3
Local Antibiotic Delivery for Community Acquired Pneumonia
Community Acquired Pneumonia (CAP)
RecruitingPhase 2
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
Asthma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing su jok therapy in people with Asthma and Dyspnea, run by Erzincan Binali Yildirim Universitesi at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dyspnea severity (time frame: Baseline and daily for 5 consecutive days, with post-intervention assessment on Day 5.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2026.